Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

Breast cancer can be classified into molecular subtypes. Tumors overexpressing HER2 protein are more aggressive and metastatic; hence, patients have a poor prognosis. Anti-HER2 strategies, such as the monoclonal antibody Trastuzumab (Tz), have therefore been developed. Despite this progress, not all...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanderhoeven, Fiorella, Redondo, Analía Lourdes, Martinez, Ana Laura, Vargas-Roig, Laura María, Sanchez, Angel Matias, Flamini, Marina Inés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995169/
https://www.ncbi.nlm.nih.gov/pubmed/29899874
http://dx.doi.org/10.18632/oncotarget.25480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995169/
https://www.ncbi.nlm.nih.gov/pubmed/29899874
http://dx.doi.org/10.18632/oncotarget.25480

Ejemplares similares